Cochrane Abstracts
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Low Molecular Weight Heparins Versus Unfractionated Heparin for Acute Coronary Syndromes." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431038/all/Low_molecular_weight_heparins_versus_unfractionated_heparin_for_acute_coronary_syndromes.
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431038/all/Low_molecular_weight_heparins_versus_unfractionated_heparin_for_acute_coronary_syndromes. Accessed April 21, 2026.
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431038/all/Low_molecular_weight_heparins_versus_unfractionated_heparin_for_acute_coronary_syndromes
Low Molecular Weight Heparins Versus Unfractionated Heparin for Acute Coronary Syndromes [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 April 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431038/all/Low_molecular_weight_heparins_versus_unfractionated_heparin_for_acute_coronary_syndromes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes
ID - 431038
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431038/all/Low_molecular_weight_heparins_versus_unfractionated_heparin_for_acute_coronary_syndromes
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
